“Did GNBT in fact create and sell vaccines for S
Post# of 36564
(Total Views: 640)
Posted On: 09/03/2021 10:56:30 PM
“Did GNBT in fact create and sell vaccines for SARS-1, the bird flu, and swine flu?”
Generex never said they sold these vaccines commercially. Of course, they created and developed them. That should be understood if you follow them. The current Covid vaccine was at first based upon the SARS research of Antigen Express (NuGen Immuno). Generex did a lot of preclinical research, but stalled due to that pandemic going away. Eric von Hofe and Dr Doug Powell (who started his career in the lab of Dr Fauci in early hiv efforts) had some big presentations for Antigen Express on bird flu. All of those earlier efforts culminated into now. However, this is where Anna always stalled, just before Phase I studies for infectious disease after a positive preliminary IND meeting.
IMHO, the investment community isn’t interested one iota in a MSO or anything in Arizona. They are, or were, interested in the vaccine efforts. Joe and Generex need success solely in this front to be taken more seriously and to recharge the IPO.
Generex never said they sold these vaccines commercially. Of course, they created and developed them. That should be understood if you follow them. The current Covid vaccine was at first based upon the SARS research of Antigen Express (NuGen Immuno). Generex did a lot of preclinical research, but stalled due to that pandemic going away. Eric von Hofe and Dr Doug Powell (who started his career in the lab of Dr Fauci in early hiv efforts) had some big presentations for Antigen Express on bird flu. All of those earlier efforts culminated into now. However, this is where Anna always stalled, just before Phase I studies for infectious disease after a positive preliminary IND meeting.
IMHO, the investment community isn’t interested one iota in a MSO or anything in Arizona. They are, or were, interested in the vaccine efforts. Joe and Generex need success solely in this front to be taken more seriously and to recharge the IPO.
(5)
(0)